Filing summary
Entity note: Although the request identifies Decoy Therapeutics Inc., the supplied Form 10-Q is for Salarius Pharmaceuticals, Inc. This summary reflects the filing as provided.
Business context and reporting period
The filing covers the quarter and nine months ended September 30, 2022. Salarius is a clinical-stage biopharmaceutical company developing cancer therapies. Its pipeline included seclidemstat (SP-2577), an LSD1 inhibitor, and SP-3164, a targeted protein degrader in IND-enabling studies. The company had no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q3 2022 / September 30, 2022 | Comparable period / prior balance |
|---|---|---|
| Revenue | $0 for Q3; $0 for the first nine months | Q3 2021: $0; nine months 2021: $1.84 million in grant revenue |
| Net loss | Q3: $14.41 million; nine months: $25.24 million | Q3 2021: $3.74 million; nine months 2021: $8.66 million |
| Research and development expense | Q3: $3.79 million; nine months: $11.15 million | Q3 2021: $2.02 million; nine months 2021: $5.85 million |
| General and administrative expense | Q3: $1.83 million; nine months: $5.35 million | Q3 2021: $1.73 million; nine months 2021: $4.66 million |
| Cash and cash equivalents | $16.82 million | $29.21 million at December 31, 2021 |
| Working capital | $14.9 million | Prior-period comparison not stated in the filing text |
| Total liabilities | $3.11 million | $2.11 million at December 31, 2021 |
Q3 and nine-month loss per share were $6.41 and $12.13, respectively, compared with $2.09 and $5.41 in the corresponding 2021 periods. Gross margin is not meaningful because the company reported no product revenue. The balance sheet lists accounts payable and accrued liabilities; it does not show a borrowing balance at September 30, 2022.
For the first nine months, operating cash used was $12.88 million, investing cash used was $1.50 million, and financing cash provided was $1.99 million. Cash declined by $12.39 million. The investing outflow was the cash portion of the SP-3164 acquisition.
Material changes versus prior periods
- Net loss increased by $10.67 million in Q3 and $16.57 million for the first nine months versus 2021. The Q3 increase included an $8.87 million non-cash goodwill impairment charge, which wrote off the full goodwill balance.
- R&D expense rose substantially, mainly reflecting SP-3164 acquisition and development spending; Q3 SP-2577 costs were lower than a year earlier, partly due to reduced manufacturing costs.
- CPRIT grant revenue ceased after available funding was exhausted in Q2 2021. The company reported a $1.61 million CPRIT receivable at September 30, 2022.
- Operating cash use increased by approximately $5.4 million from the first nine months of 2021, while financing proceeds fell sharply from $28.26 million to $1.99 million.
- Common shares outstanding were 2,249,371 at September 30, 2022, compared with 1,809,593 at December 31, 2021; the filing reports a 1-for-25 reverse split effective October 14, 2022, and historical share data is adjusted for it.
Outlook, risks, and unusual items
- Management said the $16.8 million cash balance was expected to fund anticipated operations into the second half of 2023. Separately, the filing states that substantial doubt exists about the company’s ability to continue as a going concern and that existing cash may not be sufficient for one year from issuance. Additional capital will be needed; financing plans include equity, debt, collaborations, or partnering, with no assurance of success.
- After quarter-end, a patient death in the seclidemstat Phase 1/2 trial was classified as a suspected unexpected serious adverse reaction. The company paused new enrollment on October 18, and the FDA notified the company on November 1 that the trial was on partial clinical hold. Existing patients could continue treatment after consulting their physicians; timing and prospects for restarting enrollment were uncertain.
- Management planned to submit an IND for SP-3164 in the first half of 2023. This is a stated plan, not a guarantee.
- The company completed a 1-for-25 reverse stock split on October 14, 2022. Its SP-3164 acquisition included $1.5 million cash, 40,000 shares, and potential future milestone and royalty payments.
- Other cited risks include clinical-development uncertainty, the ability to obtain financing, reliance on CPRIT and third-party research organizations, and possible COVID-19-related disruptions. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Review the FDA partial clinical hold, the SUSAR and subsequent disclosures on the seclidemstat trial, and any status changes to enrollment.
- Assess cash burn, financing needs, and the apparent tension between management’s runway estimate and the going-concern warning.
- Verify collection and timing of the $1.61 million CPRIT receivable and any grant-related obligations or repayment exposure.
- Review the goodwill impairment assumptions, SP-3164 development timetable, and potential acquisition milestone and royalty obligations.
- Check post-split share counts, outstanding warrants and options, and the potential dilution from future financing.